These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28623033)

  • 1. Anti-inflammatory profile of paricalcitol in kidney transplant recipients.
    Donate-Correa J; Henríquez-Palop F; Martín-Núñez E; Hernández-Carballo C; Ferri C; Pérez-Delgado N; Muros-de-Fuentes M; Mora-Fernández C; Navarro-González JF
    Nefrologia; 2017; 37(6):622-629. PubMed ID: 28623033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study.
    Navarro-González JF; Donate-Correa J; Méndez ML; de Fuentes MM; García-Pérez J; Mora-Fernández C
    J Clin Pharmacol; 2013 Apr; 53(4):421-6. PubMed ID: 23426718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paricalcitol for secondary hyperparathyroidism in renal transplantation.
    Trillini M; Cortinovis M; Ruggenenti P; Reyes Loaeza J; Courville K; Ferrer-Siles C; Prandini S; Gaspari F; Cannata A; Villa A; Perna A; Gotti E; Caruso MR; Martinetti D; Remuzzi G; Perico N
    J Am Soc Nephrol; 2015 May; 26(5):1205-14. PubMed ID: 25194004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients.
    Donate-Correa J; Henríquez-Palop F; Martín-Núñez E; Pérez-Delgado N; Muros-de-Fuentes M; Mora-Fernández C; Navarro-González JF
    Transplantation; 2016 Nov; 100(11):2432-2438. PubMed ID: 27467536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients.
    Pérez V; Sánchez-Escuredo A; Lauzurica R; Bayés B; Navarro-Muñoz M; Pastor MC; Cañas L; Bonet J; Romero R
    Eur J Pharmacol; 2013 Jun; 709(1-3):72-9. PubMed ID: 23567070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Paricalcitol on Bone Density After Kidney Transplantation: Analysis of 2 Transplant Centers.
    Žilinská Z; Dedinská I; Breza J; Laca L
    Iran J Kidney Dis; 2017 Nov; 11(6):461-466. PubMed ID: 29190607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study.
    Pihlstrøm HK; Gatti F; Hammarström C; Eide IA; Kasprzycka M; Wang J; Haraldsen G; Svensson MHS; Midtvedt K; Mjøen G; Dahle DO; Hartmann A; Holdaas H
    Transpl Int; 2017 Aug; 30(8):827-840. PubMed ID: 28436117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
    J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correction of secondary hyperparathyroidism with paricalcitol in renal transplant improves left ventricular hypertrophy].
    Massimetti C; Imperato G; Feriozzi S
    G Ital Nefrol; 2019 Feb; 36(1):. PubMed ID: 30758155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.
    Donate-Correa J; Domínguez-Pimentel V; Méndez-Pérez ML; Muros-de-Fuentes M; Mora-Fernández C; Martín-Núñez E; Cazaña-Pérez V; Navarro-González JF
    Mediators Inflamm; 2014; 2014():670475. PubMed ID: 24511210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
    Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
    BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism.
    Egido J; Martínez-Castelao A; Bover J; Praga M; Torregrosa JV; Fernández-Giráldez E; Solozábal C
    Nefrologia; 2016; 36(1):10-8. PubMed ID: 26705959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of paricalcitol on biomarkers of inflammation and fibrosis in kidney transplant recipients: results of a randomized controlled trial.
    Oblak M; Mlinšek G; Kandus A; Buturović-Ponikvar J; Arnol M
    Clin Nephrol; 2017 Supplement 1; 88(13):119-125. PubMed ID: 28664839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.